Author(s): Mayur S. Jain, Shashikant D. Barhate

Email(s): mayurjain176@gmail.com

DOI: 10.5958/2231-5691.2019.00042.X   

Address: Mayur S. Jain*, Dr. Shashikant D. Barhate
Shree Sureshdada Jain Institute of Pharmaceutical Education and Research, Jammer
*Corresponding Author

Published In:   Volume - 9,      Issue - 4,     Year - 2019


ABSTRACT:
Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically affect the skin, causing various types of skin lesions. On August 8 2018, the U.S. Food and Drug Administration (FDA) approved mogamulizumab injection (also known as Poteligeo) for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. Mogamulizumab is derived from Kyowa Hakko Kirin's POTELLIGENT (®) technology, which produces antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. Approval in Japan was granted on April 30 2012 by the Japanese Ministry of Health, Labour and Welfare for patients with relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma.


Cite this article:
Mayur S. Jain, Shashikant D. Barhate. Review on-Mogamulizumab is a Humanized Monoclonal Antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF). Asian J. Pharm. Res. 2019; 9(4):260-262. doi: 10.5958/2231-5691.2019.00042.X


Recomonded Articles:

Author(s): Hiral A. Makadia, Ami Y. Bhatt, Ramesh B. Parmar, Ms. Jalpa S. Paun, H.M. Tank

DOI:         Access: Open Access Read More

Author(s): Prajapati M., Mandloi R., Pillai S, Birla N.

DOI: 10.5958/2231-5691.2020.00021.0         Access: Closed Access Read More

Author(s): Mohd. Yaqub Khan, Maryada Roy, Raj Kumar Rawal, Umesh Kumar Bansal

DOI: 10.5958/2231-5691.2017.00007.7         Access: Open Access Read More

Author(s): Samir K. Shah, Kruti M. Patel, Pinal M. Vaviya

DOI: 10.5958/2231-5691.2017.00014.4         Access: Open Access Read More

Author(s): Kaustubh V. Gavali, Manohar D. Kengar, Kiran V. Chavan, Vaishnavi P. Anekar, Naziya I. Khan

DOI: 10.5958/2231-5691.2019.00020.0         Access: Closed Access Read More

Author(s): Ashok Thulluru, Nawaz Mahammed, C. Madhavi, K. Nandini, S. Sirisha, D. Spandana

DOI: 10.5958/2231-5691.2019.00016.9         Access: Closed Access Read More

Author(s): Sarika V. Khandbahale

DOI: 10.5958/2231-5691.2019.00021.2         Access: Closed Access Read More

Author(s): B. Babu Rao, P. Harish, Saikat Das, T. Ashwin Kumar, V. Raman Koundinya

DOI:         Access: Open Access Read More

Author(s): M. Kranthi Kumar Reddy, B. Narasimha Rao, K. Ravindra Reddy

DOI:         Access: Open Access Read More

Author(s): Rathnakumar K, Jaikumar S, Sengottuvelu S.

DOI:         Access: Open Access Read More

Author(s): Jagdish Jadhav, Dharmendra Mundhada, Rajesh Mujoriya

DOI: 10.5958/2231-5691.2015.00019.2         Access: Open Access Read More

Author(s): Sarika S. Lokhande

DOI: 10.5958/2231-5691.2019.00015.7         Access: Closed Access Read More

Author(s): Waghmare Sneha S., Kadam Trupti V., Darekar A. B., Saudagar R. B.

DOI: 10.5958/2231-5691.2015.00008.8         Access: Open Access Read More

Author(s): Dibyajyoti Saha, Swati Paul

DOI:         Access: Open Access Read More

Asian Journal of Pharmaceutical Research (AJPRes.) is an international, peer-reviewed journal, devoted to pharmaceutical sciences. AJPRes. publishes Original Research Articles, Short Communications..... Read more >>>

RNI: Not Available                     
DOI: 10.5958/2231–5691 


Recent Articles




Tags